The Antiemetics Drugs Market was valued at USD 6.73 billion in 2023 and is expected to reach USD 11.69 billion by 2032, growing at a CAGR of 6.36% from 2024-2032.
To Get more information on Antiemetics Drugs Market - Request Free Sample Report
This report provides a unique statistical analysis of the Antiemetics Drugs Market, presenting condition-specific incidence and prevalence figures to trace demand sources across regions. It especially monitors prescription trends by therapeutic class and geography, with the aid of a comparative picture of pharmaceutical expenditure stratified by type of payer (government, commercial, private, out-of-pocket) in 2023. The report also gives a specialized description of regulatory approvals and market access behavior, highlighting approval times and regional differences. It includes a branded vs. generic drug market share split, providing unusual insight into competitive positioning and pricing trends—factors frequently underrepresented in typical market analyses.
The U.S. Antiemetics Drugs Market was valued at USD 2.06 billion in 2023 and is expected to reach USD 3.56 billion by 2032, growing at a CAGR of 6.30% from 2024-2032.
The U.S. maintains a leading position in the North American antiemetics drugs market due to high incidences of cancer and gastrointestinal conditions, sophisticated healthcare infrastructure, and robust pharmaceutical R&D. Extensive use of chemotherapy and supportive care drugs also supports its leadership position. In addition, the availability of key market players and positive FDA approvals for emerging antiemetic treatments are the key drivers of long-term growth. Growing outpatient surgeries and increasing awareness of effective control of nausea and vomiting also aid the U.S.'s leading position in the region.
Drivers
The growing worldwide cancer burden is largely propelling the need for antiemetic medications.
Nausea and vomiting induced by chemotherapy (CINV) are two of the most unpleasant side effects for cancer patients, and they require effective antiemetic regimens. The American Cancer Society estimates that more than 1.9 million new cases of cancer were diagnosed in the U.S. alone in 2023, and a large percentage of these patients receive chemotherapy. As increasingly aggressive and advanced cancer treatments are being implemented worldwide, supportive care, including antiemetic administration, has experienced parallel growth. New developments, such as the FDA's fast-track approval of combination regimens like netupitant-palonosetron (Akynzeo), are improving the standard of care. Greater availability of guideline-based protocols by organizations like NCCN and ASCO further drives the utilization of antiemetics in oncology practice.
Expanding Surgical Procedures and Post-operative Care are driving the market growth.
The worldwide increase in surgical procedures—both elective and emergency—has been responsible for a growth in the use of antiemetics in controlling post-operative nausea and vomiting (PONV). According to the World Health Organization, an estimated 330 million surgeries are conducted annually worldwide, with a large percentage of patients in need of antiemetic therapy. PONV occurs in as many as 30% of all surgical patients and as many as 80% of high-risk patients. With increasing awareness of the trend toward minimally invasive and ambulatory surgeries, healthcare professionals are more concerned about maximizing recovery pathways, for which antiemetic therapy is instrumental. Recent innovations have entailed the broader clinical application of medications such as ondansetron and dexamethasone in Enhanced Recovery After Surgery (ERAS) regimens. This trend, coupled with increased patient satisfaction expectations, further underscores the sustained demand for antiemetic therapies.
Restraint
Adverse Effects and Drug Interactions Limiting Long-Term Use are restraining the market growth.
Even though they have therapeutic advantages, antiemetic drugs tend to be accompanied by a variety of side effects that may restrict their long-term or extensive utilization. Sedation, dizziness, constipation, extrapyramidal side effects, and QT interval prolongation are some general side effects that occur with dopamine receptor antagonists and serotonin (5-HT3) receptor antagonists. These side effects can hurt patient compliance and physician prescribing behavior, particularly in sensitive patients such as the elderly, pediatric patients, or cardiovascular patients. Additionally, drug–drug interactions are of increasing importance, as the majority of antiemetic users are already placed on polypharmacy therapy, particularly in oncology and post-surgical settings. For instance, coadministration of aprepitant with warfarin or dexamethasone necessitates meticulous dose adjustment. These safety issues tend to require alternative treatments or further surveillance, thus serving as a deterrent to the development and use of antiemetic drugs.
Opportunities
Growth in Emerging Markets and Access to Generics are creating the opportunity for the market.
The growth of healthcare infrastructure and enhanced pharmaceutical availability in emerging markets offer a robust growth prospect for the antiemetics drugs market. Nations in Asia Pacific, Latin America, and regions of Africa are experiencing growing cancer incidence, higher surgical volumes, and wider awareness of gastrointestinal disorders—conditions that frequently necessitate antiemetic therapy. Moreover, government efforts to make essential drugs part of public health programs have made access to cheap generic antiemetics such as ondansetron and metoclopramide more widespread. Generic players are also focusing on these markets more and more because of their cost advantages and volume-driven demand. With better health care funding, auspicious regulatory reforms, and increasing numbers of retail pharmacies and hospital chains, these areas present attractive markets for both branded and generic antiemetic drugs and provide pharmaceutical firms with an untapped but fast-expanding consumer base.
Challenges
Patent Expiry and Intense Generic Competition are challenging the market to grow.
Some of the major challenges in the antiemetics drugs market include patent expiration of key branded drugs, which have brought in generic versions. This change has heightened price-based competition, particularly in mature markets such as North America and Europe, where cost-containment pressure is intense. Branded products such as Zofran (ondansetron) and Emend (aprepitant) have suffered generic erosion, significantly affecting revenue streams of originators. With healthcare systems emphasizing cost-containment, payers tend to favor generics over branded drugs, making it challenging for producers to sustain premium pricing. Further, the large number of generic entrants has led to price deflation and compressed profit margins. For pharmaceutical firms, the survival of market share in such a competition requires a heavy investment in brand differentiation, combination therapy, and lifecycle management strategies, which are time-consuming and resource-intensive.
By Drug Type
The serotonin-receptor antagonist segment dominated the antiemetic drugs market with 28.45% market share in 2023. Due to their extensive clinical use, excellent efficacy, and favorable safety profile in treating nausea and vomiting, particularly in chemotherapy, radiation, and post-operative settings. Because they can block 5-HT3 receptors both centrally and peripherally, medications like ondansetron, granisetron, and palonosetron are regarded as the gold standard for treating chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV). Furthermore, these medications are prescribed more frequently because they are listed in important international clinical guidelines (such as the NCCN, ASCO, and MASCC) for first-line antiemetic treatment. The segment also benefits from the availability of generics and a broad range of dosage forms (oral, injectable, and ODT), which have increased accessibility in both developed and emerging markets. Serotonin-receptor antagonists were positioned as the top drug class in 2023 due to their strong combination of clinical reliability and commercial availability.
By Application
The chemotherapy segment dominated the antiemetics drugs market with a 46.10% market share in 2023 because of the high incidence of cancer worldwide and the extensive use of cytotoxic agents, which frequently cause nausea and vomiting. Antiemetic regimens are routinely prescribed as part of standard oncological care because chemotherapy-induced nausea and vomiting (CINV) is still one of the most upsetting side effects for cancer patients. Particularly in wealthy nations with access to cutting-edge cancer treatment protocols, the use of multidrug antiemetic protocols, which frequently include corticosteroids, neurokinin-1 receptor antagonists, and serotonin-receptor antagonists, has grown dramatically. Widespread use has also been made easier by regular revisions to clinical practice guidelines, the addition of antiemetics to national formularies, and insurance coverage. In 2023, chemotherapy was firmly established as the main application area due to its clinical necessity and regulatory backing.
The post-operative Surgery segment is forecasted to experience the fastest growth in the forecast years, fueled by the global increase in elective and minimally invasive surgeries. Enhanced Recovery After Surgery (ERAS) guidelines, increasingly implemented in hospitals and operating centers, focus on preventing post-operative nausea and vomiting (PONV) to minimize patient discomfort and length of hospital stay. PONV occurs in as many as 80% of high-risk surgical patients, and antiemetic administration is an essential part of perioperative management. Improved anesthesia, reduced hospital stays, and increased day-care procedures further increase the need for effective and well-tolerated antiemetics with rapid onset of action. The increase in outpatient procedures, combined with initiatives to enhance post-operative patient satisfaction and safety, is expected to drive aggressive growth in this segment in both developed and emerging healthcare systems.
By End-use
The Retail Pharmacy segment dominated the Antiemetics Drugs Market with 50.09% market share in 2023 because of the growing demand for over-the-counter (OTC) and prescription-based antiemetic drugs, especially for general conditions such as motion sickness, gastroenteritis, and nausea during pregnancy. Retail pharmacies provide an easy and accessible point of care for patients who require instant relief, particularly in non-hospital settings. Ease of access to generics like ondansetron, domperidone, and promethazine in tablet and dissolvable presentations has further promoted self-medication and intervention by pharmacists. The international spread of retail pharmacy chains and e-pharmacy sites has been a driving force behind enhanced access to antiemetics in both urban and semi-urban parts of the country. As customers become more aware of their available medication choices and the use of outpatient care and telemedicine prescriptions gains ground, they are relying more on retail channels for their medication requirements. These trends, in combination, served to reinforce the preeminence of retail pharmacies in 2023.
North America dominated the antiemetics drugs market with a 37.23% market share in 2023 due to its well-developed healthcare infrastructure, high level of health expenditures, and prominent foothold of major pharmaceutical companies. The region has a high prevalence of diseases like cancer, gastrointestinal disorders, and post-operative conditions that frequently necessitate antiemetic therapy. Support from authorities such as the FDA, combined with expedited drug approvals and widespread insurance coverage, additionally contributes to market expansion. Furthermore, early uptake of cutting-edge therapies and a wide patient base that is receiving chemotherapy and other therapies causing nausea and vomiting support North America's market dominance.
Asia Pacific is the fastest-growing region in the antiemetics drugs market with 6.32% CAGR as a result of improving healthcare awareness, rising access to medical facilities, and enhanced investments in healthcare infrastructure. The area is experiencing growth in cancer and gastrointestinal disease incidence, along with rising diagnostic rates. Growing pharmaceutical markets in China and India, favorable government policies, and greater availability of generics make antiemetic treatments more available and cost-effective. In addition, a vast population base and changing treatment patterns play an important role in the high-speed market growth in the Asia Pacific.
Get Customized Report as per Your Business Requirement - Enquiry Now
Pfizer Inc. (Zofran, Phenergan)
GlaxoSmithKline plc (Zofran ODT, Kytril)
Johnson & Johnson (Emend, Motilium)
Sanofi S.A. (Aloxi, Domperidone)
Novartis AG (Zofran Injection, Compro)
Merck & Co., Inc. (Emend IV, Aprepitant)
Baxter International Inc. (Prochlorperazine, Ondansetron Injection)
F. Hoffmann-La Roche Ltd (Aloxi, Kytril Injection)
Boehringer Ingelheim International GmbH (Metoclopramide, Granisetron)
Teva Pharmaceutical Industries Ltd. (Ondansetron, Prochlorperazine Maleate)
Dr. Reddy's Laboratories Ltd. (Domperidone, Ondansetron ODT)
Mylan N.V. (Meclizine Hydrochloride, Promethazine Hydrochloride)
Sun Pharmaceutical Industries Ltd. (Granisetron Injection, Palonosetron)
Cipla Ltd. (Domperidone Suspension, Ondansetron Tablets)
Aurobindo Pharma Ltd. (Prochlorperazine Tablets, Granisetron Tablets)
Torrent Pharmaceuticals Ltd. (Levocetirizine + Montelukast, Domperidone MD)
Zydus Lifesciences Ltd. (Ondem, Vomistop)
Lupin Limited (Emeset, Domstal)
AbbVie Inc. (Marinol, Maviret [used adjunctively])
Endo International plc (Promethegan, Zenzedi [off-label use])
Suppliers (These suppliers primarily provide pharmaceutical excipients such as binders, disintegrants, coatings, stabilizers, and API intermediates essential for formulating antiemetic drugs across various delivery forms like tablets, injections, and oral suspensions) in the Antiemetics Drugs Market
BASF SE
Evonik Industries AG
Ashland Global Holdings Inc.
DuPont de Nemours, Inc.
Colorcon Inc.
DFE Pharma
Roquette Frères
Lubrizol Life Science
Croda International Plc
Merck KGaA (MilliporeSigma)
March 11, 2025 – Arvinas, Inc. and Pfizer Inc. announced positive Phase 3 VERITAC-2 trial data, demonstrating vepdegestrant monotherapy superiority over fulvestrant in ER+/HER2- advanced breast cancer patients who had been treated with CDK4/6 inhibitors and endocrine therapy. Vepdegestrant is an oral PROTAC ER degrader with potential first-in-class properties.
June 3, 2024 – The IMROZ Phase 3 trial demonstrated that Sarclisa (isatuximab) in combination with VRd and then Sarclisa-Rd decreased the risk of disease progression or death by 40% compared with VRd and then Rd in patients with newly diagnosed, transplant-ineligible multiple myeloma.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 6.73 Billion |
| Market Size by 2032 | US$ 11.69 Billion |
| CAGR | CAGR of 6.36 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Type (Serotonin-Receptor Antagonists, Anticholinergics, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Others [Antihistamines, Cannabinoids]) • By Application (Chemotherapy, Gastroenteritis, Post-Operative Surgery, Others [Vertigo, Motion Sickness]) • By End-use (Hospital & Clinics, Retail Pharmacy, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis AG, Merck & Co., Inc., Baxter International Inc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Lupin Limited, AbbVie Inc., Endo International plc, and other players. |
Ans: The Antiemetics Drugs Market is expected to grow at a CAGR of 6.36% from 2024-2032.
Ans: The Antiemetics Drugs Market was USD 6.73 billion in 2023 and is expected to reach USD 11.69 billion by 2032.
Ans: The growing worldwide cancer burden is largely propelling the need for antiemetic medications.
Ans: The “Serotonin-Receptor Antagonists” segment dominated the Antiemetics Drugs Market.
Ans: North America dominated the Antiemetics Drugs Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends (2023), by Region
5.3 Pharmaceutical Spending, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
5.4 Regulatory Approvals and Market Access (2023)
5.5 Generic vs. Branded Drug Market Share (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Antiemetics Drugs Market Segmentation, By Drug Type
7.1 Chapter Overview
7.2 Serotonin-Receptor Antagonists
7.2.1 Serotonin-Receptor Antagonists Market Trends Analysis (2020-2032)
7.2.2 Serotonin-Receptor Antagonists Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Anticholinergics
7.3.1 Anticholinergics Market Trends Analysis (2020-2032)
7.3.2 Anticholinergics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Dopamine Receptor Antagonists
7.4.1 Dopamine Receptor Antagonists Market Trends Analysis (2020-2032)
7.4.2 Dopamine Receptor Antagonists Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Neurokinin Receptor Antagonists
7.5.1 Neurokinin Receptor Antagonists Market Trends Analysis (2020-2032)
7.5.2 Neurokinin Receptor Antagonists Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others (Antihistamines, Cannabinoids)
7.6.1 Others (Antihistamines, Cannabinoids) Market Trends Analysis (2020-2032)
7.6.2 Others (Antihistamines, Cannabinoids) Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Antiemetics Drugs Market Segmentation, by Application
8.1 Chapter Overview
8.2 Chemotherapy
8.2.1 Chemotherapy Market Trends Analysis (2020-2032)
8.2.2 Chemotherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Gastroenteritis
8.3.1 Gastroenteritis Market Trends Analysis (2020-2032)
8.3.2 Gastroenteritis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Post-Operative Surgery
8.4.1 Post-Operative Surgery Market Trends Analysis (2020-2032)
8.4.2 Post-Operative Surgery Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others (Vertigo, Motion Sickness)
8.5.1 Others (Vertigo, Motion Sickness) Market Trends Analysis (2020-2032)
8.5.2 Others (Vertigo, Motion Sickness) Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Antiemetics Drugs Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospital & Clinics
9.2.1 Hospital & Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospital & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacy
9.3.1 Retail Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacy
9.4.1 Online Pharmacy Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.4 North America Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.5 North America Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.6.2 USA Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.6.3 USA Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7.2 Canada Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.7.3 Canada Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7.2 France Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.7.3 France Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6.2 China Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.6.3 China Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7.2 India Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.7.3 India Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8.2 Japan Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.8.3 Japan Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12.2 Australia Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.12.3 Australia Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.4 Africa Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.5 Africa Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Antiemetics Drugs Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.4 Latin America Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.5 Latin America Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Antiemetics Drugs Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Antiemetics Drugs Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Antiemetics Drugs Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
11. Company Profiles
11.1 Pfizer Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 GlaxoSmithKline plc
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Johnson & Johnson
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Sanofi S.A.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Novartis AG
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Merck & Co., Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Baxter International Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 F. Hoffmann-La Roche Ltd
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Boehringer Ingelheim International GmbH
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Antiemetics Drugs market Key Segments:
By Drug Type
Serotonin-Receptor Antagonists
Anticholinergics
Dopamine Receptor Antagonists
Neurokinin Receptor Antagonists
Others (Antihistamines, Cannabinoids)
By Application
Chemotherapy
Gastroenteritis
Post-Operative Surgery
Others (Vertigo, Motion Sickness)
By End-Use
Hospital & Clinics
Retail Pharmacy
Online Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Artificial Teeth Market was USD 1.87 billion in 2023 and is expected to reach USD 3.83 billion by 2032, growing at a CAGR of 8.32% by 2024-2032.
The Neurorehabilitation Market was valued at USD 1.95 billion in 2023 and expected to reach USD 6.18 billion by 2032, at a CAGR of 13.68%.
Healthcare Claims Management Market was valued at USD 15.01 Bn in 2023 and is expected to reach USD 24.93 Bn by 2032, growing at a CAGR of 5.85% from 2024-2032.
The Huntington’s Disease Treatment market size was USD 445.90 million in 2023 and is expected to reach USD 2670.13 million by 2032 and grow at a CAGR of 22.00% over the forecast period of 2024-2032.
The Cancer Biologics Market Size was valued at USD 102.2 Billion in 2023 and is expected to reach USD 195.5 Bn by 2032, with a growing CAGR of 7.5% Over the Forecast Period of 2024-2032.
The Subcutaneous Drug Delivery Devices Market was worth USD 30.92 billion in 2023 and is predicted to be worth USD 56.95 billion by 2032, growing at a CAGR of 7.07% between 2024 and 2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
